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Outcome of Endovascular Treatment in
Symptomatic Intracranial Vascular
Stenosis
Objective: The outcome evaluation for the revascularization of intracranial vas-
cular stenoses has not been fully described due to the highly technical nature of
the procedure. We report here on the early and late clinical outcomes of angio-
plasty and/or stenting of symptomatic severe intracranial vascular stenoses at a
single institute.
Materials and Methods: Since 1995, we have treated 35 patients with sympto-
matic intracranial vascular stenosis (more than 70% stenosis, mean stenosis:
78.6% 6.2%). Angioplasty (n = 19) was performed for the horizontal segment of
the middle cerebral artery (M1) (n = 16) and the basilar artery (BA) (n = 1), the
intradural vertebral artery (VA) (n = 1), and the cavernous internal carotid artery
(ICA) (n = 1). Stenting (n = 16) was performed for the cavernous or petrous ICAs
(n = 9), the intradural VA (n = 3), BA (n = 2), and M1 (n = 2) artery. We assessed
the angiographic success (defined as residual stenosis < 50%) rate, the peripro-
cedural complications during the 30-day periprocedural period, the symptomatic
recurrence and restenosis during a mean 22-month follow-up (FU) period. The
Kaplan-Meier estimate of the cumulative event-free rate of the major cerebrovas-
cular events, i.e. death, stroke or restenosis, was also done.
Results: Angiographic success was achieved in 97% of our patients (34/35).
There were four procedure-related complications (11%) including a death and a
minor stroke. During the mean 22-month FU, the asymptomatic restenosis rate
was 9% and the symptomatic restenosis rate was 6% in the target lesion and 9%
in all the vascular territories. The Kaplan-Meier estimate was 70.6% (95% confi-
dence interval = 46.5 94.7) after 33 months of FU. 
Conclusion: In addition to a high angiographic success rate and an acceptable
periprocedural complication rate, intracranial angioplasty and/or stenting revealed
a relatively low symptomatic recurrence rate. Hemorrhage is a rare, but the physi-
cian must aware that potentially fatal periprocedural complications can occur.
ntracranial atherosclerosis is a major cause of ischemic stroke, and
depending on the studied population, it accounts for 8 15% of all
strokes that are due to cerebral atherosclerosis (1 5). In a retrospective,
nonrandomized review of 151 patients in the United States, the annual rate of stroke
for patients with symptomatic severe intracranial stenosis was 10.7% in the aspirin-
treated group (6). Annual stroke rates reach 15.0% for patients with basilar artery
stenosis and 13.7% for patients with vertebral artery stenosis (7). Thijs et al. (8) have
reported that those patients with symptomatic intracranial atherosclerosis who failed
at antithrombotic therapy, they revealed a very high rate of cerebral ischemic events
(55.8%), e.g., 29 of the 52 study patients. 
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IExtracranial-intracranial anastomosis has not been
proven to be effective for preventing cerebral ischemia in
those patients with atherosclerotic arterial disease in the
carotid and middle cerebral arteries (9). In the report by
the EC/IC Bypass Study Group (9), non-fatal and fatal
strokes occurred earlier and more often in patients who
underwent bypass surgery and the patients with severe
middle cerebral artery stenosis had the worst outcomes.
Bypass surgery also resulted in an 8% mortality rate and a
13% morbidity rate for 83 patients having symptomatic
vertebrobasilar insufficiency who underwent 85 bypass
procedures (10).
Although endovascular revascularization for sympto-
matic intracranial stenoses remains at the investigational
stage and much of the pertinent information is anecdotal,
intracranial angioplasty and stenting are being increasingly
performed to treat stenotic lesions (11). The complication
rates range from 0 50% (12 23). The possible reasons
why the outcomes of angioplasty and stenting procedures
vary greatly from center to center have not yet been
identified. In addition, any direct comparison of the
relevant literature results is difficult because there is no
uniformity of the procedures’ protocols and of the methods
for evaluating the results, and there are also ethnic differ-
ences in the incidence of intracranial stenosis. For Koreans,
severe atherosclerotic stenoses tend to be more intracranial
stenoses than extracranial stenoses (3). 
We report here on our results for angioplasty/stenting of
the intracranial arteries in 35 consecutive patients. We
have included the early and late clinical outcomes, and we
compared our results to the results that have been reported
in the literature. 
MATERIALS AND METHODS
Since 1995, we have treated 35 consecutive patients
with severe (more than 70%) symptomatic intracranial
stenosis. Nine patients from the authors’ previous reports
(14, 24) were included along with their full follow-up (FU)
data. The patients’ ages ranged from 31 to 73 years (mean
age: 53), and the male to female ratio was 3.4:1.
Angioplasty (n = 19) was done in the M1 segment of the
middle cerebral artery (M1) (n = 16) (Figs. 1, 2), the basilar
artery (BA) (n = 1), the intradural vertebral artery (VA) (n
= 1), and the cavernous internal carotid artery (ICA) (n =
1). Stenting (n = 16) was done in the cavernous (n = 8) or
petrous (n = 1) ICA (Fig. 3), the intradural VA (n = 3), the
basiler artery (BA) (n = 2), and the M1 segment of the
middle cerebral artery (M1) (n = 2). This report did not
include any patients who were treated as part of
emergency protocols or those patients with intracranial
occlusion. For each patient, a complete history taking and
a neurological examination were performed by an
independent neurologist who was not involved in the
interventional procedure. Our data revealed that types of
procedure were different among the lesion sites;
angioplasty was performed more often in the M1 segment
in contrast to stenting being performed in the posterior
circulation and in the cavernous segment of the ICA (p <
0.001).
Angio-interventional Procedures
Most patients were premedicated with 100 mg of acetyl-
salicylic acid (ASA) and either 75 mg of clopidogrel
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Fig. 1. A 60-year-old female patient presented with dysarthria and right arm weakness of 20 days duration. 
A. The anterioposterior view of the left internal carotid arteriogram shows a severe stenosis of the horizontal segment of the left middle
cerebral artery. 
B. The flow improves after angioplasty. 
C. MR angiogram obtained 68 months later reveals good patency of the horizontal segment of the left middle cerebral artery. She had no
symptom recurrence and no residual symptoms.
AB C(Plavix, Sanofi, Inc) or 250 mg of ticlopidine (Ticlid,
Roche, Inc) for at least four days before the procedure.
One hundred milligrams of ASA (low dose regimen) once
daily was continued as a permanent medication.
Additionally, 75 mg of clopidogrel were given once daily
for more than six months following the procedures. All the
procedures were performed under local anesthesia, and
during the procedures, each patient received 5,000 8,000
IU of intravenous heparin to attain an activated clotting
time (ACT) of more than 250 seconds. Prior to treatment,
diagnostic cerebral angiography was performed via the
transfemoral approach. The procedure started with a
common carotid artery injection, and this was followed by
selective angiography of both the internal carotid and
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Fig. 2. A 62-year-old male presented with right side weakness and global aphasia. 
A. Angiogram of the left internal carotid artery shows a severe stenosis in the horizontal segment of the left middle cerebral artery. 
B. The angiogram obtained after angioplasty shows the relieved stenosis and improved flow. The patient’s symptoms slowly improved
except for some mild weakness and expressive aphasia that remained after there was symptom aggravation two years later. 
C. MR angiography obtained at the time of the symptom aggravation reveals complete occlusion of the left horizontal segment of the left
middle cerebral artery.
AB C
Fig. 3. A 49-year-old male presented with the left arm weakness. 
A. Lateral view of the right internal carotid arteriogram shows a severe stenosis of the cavernous segment of the internal carotid artery.
B. Post-stenting angiogram shows no residual stenosis. 
C. One-year follow-up angiogram shows good patency of the stented segment of the internal carotid artery with a 20% stenosis at the
distal stent margin. Note a patent side branch of the cavernous segment of the internal carotid artery. The patient recovered completely
and had no symptom recurrence during the one-year follow-up period.
AB Cvertebral arteries.
A 6F sheath was introduced and it was then positioned in
either the internal carotid artery or the vertebral artery.
The sidearm of the guiding catheter was continuously
flushed with pressurized, heparinized normal saline, and
this catheter was used for angiography treatment steps.
After crossing the lesion with a 0.010 0.014-inch outer
diameter microguidewire, the balloon catheter was placed
over the microguidewire and next directed across the
lesion. We used balloon catheters with diameters ranging
from 2 to 3 mm and with lengths of 10 or 20 mm accord-
ing to the target vessel size, and we were careful not to
allow any over-dilatation. Balloon inflation was performed
slowly and maintained for 10 to 20 seconds with a dispos-
able inflation device that allowed for exact pressure
control.
In the 16 stenting procedures, the stenotic lesion was
predilated with a balloon catheter 2 mm in diameter and
10 20 mm in length in all cases. A stent 2 4 mm in
diameter and 8 18 mm in length was passed over the
guidewire and positioned across the stenosis. Each stent
was selected according to the size of the target vessel. The
residual stenosis of the treated intracranial artery was
measured via post-procedural angiography. As the more
flexible and lower profile stents have become available,
our approach has changed from performing angioplasty
alone to performing angioplasty followed by stenting at the
same session: this has been done on a more routine basis
than was previously done before 2002.
Measurement of Stenosis
The percentage of the diameter of the stenosis was
calculated by dividing the narrowest linear diameter at the
stenotic segment by the distal diameter at the segment of
the same vessel that had a normal appearance (25). Lesion
length and eccentricity were measured and categorized
according to Mori’s classification (13) and these parameters
were analyzed for comparison of treatment outcome. An
eccentric lesion was defined as when the residual lumen
was asymmetrically shifted to one wall of the vessel due to
the eccentrically located plaque. Restenosis was evaluated
by using transcranial Doppler and/or cerebral angiography.
FU Evaluation
We obtained the clinical data, with the exception of the
data for one patient who died, during a mean 22-month
FU period (FU range: 3 86 months, median FU: 13). In
addition to the clinical FU, MR angiography (MRA) was
obtained in 11 patients (Figs. 1, 2), conventional angiogra-
phy was done for 10 patients (Fig. 3), CT angiography was
done for one patient, and transcranial Doppler (TCD) was
done for only five patients. The mean imaging study FU
period including the TCD was 21 months (range: 3 74,
median: 11). Only the clinical FU without the imaging
studies was available for seven patients. Two of these
seven patients were followed for less than six months
(three and four months) and other five patients did not
undergo angiographic FU. 
Evaluation of Outcome and Statistical Methods
We evaluated angiographic success rate, the periproce-
dural complications during the 30 days periprocedural
period, and the symptomatic recurrence and restenosis
during a mean 22-month FU period. The angiographic
success, as calculated on a per-vessel basis, was defined as
any residual stenosis < 50%. Angiographic restenosis on
conventional cerebral angiography was defined as a
stenosis > 50% of the luminal diameter. MR angiography
FU was mainly used for those patients who only received
angioplasty and the degree of stenosis on MRA was based
on the interpretations by the staff neuroradiologists.
Doppler ultrasonic restenosis was defined as an increased
peak systolic velocity threshold of 220 cm/sec for the
intracranial internal carotid artery and the proximal middle
cerebral artery; the corresponding thresholds were 140
cm/sec for the basilar artery and 120 cm/sec for the
vertebral artery (26). Minor stroke was defined as a new
non-disabling neurological deficit or an increase of 3 on the
National Institutes of Health Stroke Scale (27), or a non-
fatal hemorrhage that completely resolved within 30 days.
Major stroke was defined as a new neurologic deficit that
persisted beyond 30 days and an increase of 4 according to
the National Institutes of Health Stroke Scale. 
The cumulative event-free rate of major adverse
cerebrovascular events (MACEs), i.e. death, stroke or
restenosis was analyzed by the Kaplan-Meier method.
MACEs included stroke, death and restenosis with or
without a symptomatic recurrence during the FU. The log-
rank test was used to compare MACEs between the M1
segment of middle cerebral artery and the other sites in the
intracranial arteries. We used x
2 or Fisher’s exact tests to
compare the differences of MACEs between angioplasty
and stenting procedures and for the lesion length, lesion
eccentricity and the location of the lesions. All the calcula-
tions were performed with SPSS for Windows (version
10.0, SPSS Inc).
Repeated angioplasty or repeated stenting during the FU
period was not attempted for our patients. We compared
our results with the relevant long-term outcomes in the
currently available literature (Table 1). 
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The mean degree of stenosis in the symptomatic intracra-
nial artery was 78.6% 6.2%. After the procedure, the
mean residual stenosis was 20.7% 14.4%. Angiographic
success (less than 50% residual stenosis) was achieved in
97% of the patients, and the only exception was one
patient who had an asymptomatic dissection (34/35). 
Periprocedural complications within the first 30 days
were noted in four patients (11%), and this included an
aymptomatic dissection at M1 and a transient ischemic
attack at M1. There was a minor stroke in one patient
(3%) who experienced a subarachnoid hemorrhage that
was due to a guidewire-related arterial perforation, but it
resulted in only a transient headache. There was one death
due to hemorrhage during a BA stenting (3%). 
There was no recurrence of symptoms within one year
period (Figs. 1, 3). During the mean 22-month total FU
period, symptomatic restenosis/occlusion related to the
target lesion was noted in two patients (symptomatic
restenosis, 6%). One patient had an ischemic stroke that
was not related to the treated vessel. Asymptomatic
restenosis was detected in three patients (9%) during the
FU period.
Among the three symptomatic patients we observed
during FU, one patient experienced aggravation of a
neurologic deficit that was related to an occlusion at the
M1 segment 24 months after the angioplasty procedure
(Fig. 2). Another patient had an intracerebral hematoma
and intraventricular hemorrhage that was associated with
M1 occlusion 16 months after the angioplasty procedure,
but this patient experienced a full recovery by the time of
the 33-month FU examination. The other patient revealed
an ipsilateral internal carotid artery occlusion on MRA at
the time of a pontine infarction 20 months after the
procedure; this led to some mild weakness of the patient’s
extremities. 
The Kaplan-Meier curves predicted that the cumulative
event-free rate of MACEs, i.e. death, stroke or restenosis,
was 70.6% (95% confidence interval = 46.5 94.7) at 33
months. The log rank test for the difference in the cumula-
tive event-free rate of MACEs according to the lesion site
showed no statistical significance. There were also no
significant differences in MACEs among the types of
procedures, the lesion lengths and the lesion eccentricities. 
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Table 1. Comparison of Complication Rates in the Literature
Author
Peri-procedural Cx within 30 days
(reference Year
No of Pts 
Procedure Location of Lesion
TIA Minor Major Death(#)
MACE 
Restenosis 
number)
(*) during FU
Takis (12) 1997 7 (2) AP 5va, 3ica, 1M1, 1ba 0 2 2 0 (1) NA NA
Mori (13) 1998 42 AP 21mca, 8ica, 6va, Fatal and nonfatal ipsilateral stroke
5ba, 2pca Type A 8%, B 12%, C 56% 9/32 (28%) at 12m
Suh (14, 24) 1999 9 (1) AP 9M1 1 0 0 0 0 at 11m NA
Marks (15) 1999 23 (1) AP 8va, 7ica, 4ba,  0 1 0 1 (1) 2 at 32, 37m NA
3mca, 1pca 
Nahser (16) 2000 20 AP 14va, 6ba 0 1 1 0 1 at 4m 2/14 (14%)
Gomez (17) 2000 12 Stent ba 1 0 0 0 0 at 6m NA
Levy (18)  2001 11 AP Stent va, ba 0 0 1 3 0 0/7 at 4m
Lylyk (19) 2002 34 AP stent 15ica, 11d-va, 3vbj,  2 0 0 2 (1) 2 at 5m 0/20 at 6m
2ba, 3 mca
Levy (20) 2002 8 Stent 4ba, 3vbj, 1 p-va 0 0 1 0 1 0 60% in 4 at 27m
Gupta (21) 2003 17 (1) AP stent 6mca, 6ica, 3ba, 3va 0 3 3  1 (2) NA NA
Levy (22) 2003 10 Stent  8ba, 2vbj 1 1 2 0 (2) 0 NA
de Rochemont 
Rdu (23) 2004 18 (2) Stent  7ica, 6va, 5ba, 2mca  0 0 1 0 (1) 0 at 6m 0 at 6m
Jiang (33) 2004 40 stent  40mca  1 2 0 1 1/7
Suh et al. 2004 35 AP stent 18M1, 10ica, 4va, 3ba 1 1 0 1 3 at 16,  6% Sx 
20, 24 m restenosis 
Note. (*) = number of patients not attempted, (#) = death from other causes during follow-up, Cx = complication, AP = angioplasty, ica = internal carotid
artery, d-va = distal vertebral artery, p-va = proximal vertebral artery, vbj = vertebrobasilar junction, ba = basilar artery, mca = middle cerebral artery, s =
stroke, MACE = major adverse cerebrovascular event (nonfatal cerebral infarct or hemorrhage, revascularization), FU = follow-up, m = month(s), NA = not
available, Sx restenosis = symptomatic restenosis related to the target vessel, Mori type A 5 mm; type B = 5 to 10 mm; type C 10 mm in lesion lengthDISCUSSION
Our experience in this study indicated that 97% of our
study patients achieved angiographic success (34/35). The
incidence of symptomatic restenosis was very low after
angioplasty and/or stenting of intracranial stenoses, i.e.
6%, during a mean 22 months of FU. The symptomatic
recurrence rate in any vascular territory was 9% during
the same FU period. However, intracranial angioplasty and
stenting had a 3% fatal complication rate, although our
fatality rate was less than those fatality rates reported in
the literature (Table 1). 
Because the symptomatic recurrence rate was as high as
9% and it seemed to go higher with further long term FU,
the physician is required to make a therapeutic decision for
those patients with asymptomatic restenosis. Our policy
has been to observe these patients closely while they are
under medication because symptomatic restenosis is
regarded as the only indication for a revascularization
procedure including repeated angioplasty and/or stenting.
The recent advent of new generation stents that have
low profiles and high flexibility has encouraged the consid-
eration of performing stent-assisted angioplasty as an
alternative approach to angioplasty alone for intracranial
stenosis (17 23). Presently, the primary limitation of
angioplasty appears to be restenosis (defined as more than
50% diameter stenosis on FU angiography), and this is
seen in as many as 30% to 40% of the patients who are
treated by coronary angioplasty (28). 
The complication rates of intracranial angioplasty and
stenting are known to be very high, i.e. from 0 to 50%
(12 23). The mortality rate was 3% in our study. The
periprocedural mortality and morbidity rate also seem to
be higher after stenting than for an angioplasty procedure
alone (21, 22). Bleeding is a serious complication for
intracranial stenting as was seen in one of our study
patients. The causes of bleeding include a bleeding
tendency caused by aggressive antiplatelet and anticoagu-
lation therapy, hyperperfusion syndrome, vessel rupture or
dissection due to ballooning and/or stenting, and guidewire
injury. The subarachnoid hemorrhage due to a guidewire
injury in a patient of our study had a relatively benign
clinical course without further symptomatic problems at
four months clinical FU. In addition to the hemorrhagic
complications, infarctions related to thromboemboli or to
side-branch occlusion due to the presence of the deployed
stent also contribute to the fatal peri-procedural complica-
tions. We only experienced one transient ischenic attack in
a patient after angioplasty of the M1 segment.
One of the major concerns in intracranial stenting is the
side branch occlusion that can be caused by the stent struts,
although we did not experience any problem related to the
perforator or side branch occlusion. The possible
mechanism for side branch occlusion after stenting in the
coronary artery is the ‘snow plow’ effect where the
atheroma from the parent vessels is shifted into the ostium
of a side branch (29, 30). Other mechanisms for side
branch occlusion may include side branch spasm,
embolization of the atherosclerotic material, thrombus
formation and the stent material itself. The presence of
ostial narrowing arising from within or just beyond the
diseased portion of the parent vessel was the most
powerful predictor of side branch occlusion in the coronary
artery immediately after stenting (30). The plaque volume
of the parent vessel and the side branches is a major
determinant for the fate of the side branches.
Perforaters in M1 and BA are different from the side
branches in the coronary vessels in that the perforators are
terminal branches supplying the deep nuclei of the basal
ganglia and brainstem. Experimental evidence from canine
vertebral arteries suggests that the cervical muscular
branches, which are comparable to human perforators,
tend to remain patent if less than 50% of the ostial
diameter is covered by the stent strut (31). A size compari-
son between the stents and the perforators should be made
in order to avoid any compromised flow in the perforators
(32). 
In conclusion angioplasty and/or stenting of the intracra-
nial arteries are relatively safe procedures having a high
angiographic success rate (97%), an acceptable rate of
periprocedural complication (11%), which included a
minor stroke and a death within 30 days, and a low
symptomatic restenosis rate for the target lesion (6%) and
for all the vascular territories (9%) during the mean 22-
month FU. Replacement of intracranial revascularization
by stenting needs to be further studied in conjunction with
the advent and arrival of new stent devices that have high
flexibility and low profiles.
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